| Zero-Order Drug Delivery |
| Administration route | Drug delivery , Inflammation/Musculoskeletal , Cardiovascular , Neurological |
| Indication | Useful for oral drug delivery when constant blood level of drug is required over 12 or 24 hours |
| Licence code | LO-1107-24 |
| Beta Blocker Therapeutics for Osteoporosis, Fracture Repair and Other Bone Disorders |
| Administration route | Oral |
| Indication | Osteoporosis |
| Licence code | LO-1107-22 |
| Synthesis of Oligo/Poly(Catechins) and Methods of Use |
| Administration route | Undisclosed |
| Indication | Cancer |
| Licence code | LO-1107-17 |
| Compositions and Methods for Making and Using Nanoemulsions |
| Administration route | Transdermal |
| Indication | Drug delivery |
| Licence code | LO-1107-16 |
| Antioxidant Synergy Formulation Nanoemulsions to Treat Cancer |
| Administration route | Transdermal |
| Indication | Delivery of cancer therapeutics |
| Licence code | LO-1107-15 |
| Microspheres and Nanospheres Based on Natural Materials |
| Administration route | Transdermal, Oral |
| Indication | Drug delivery |
| Licence code | LO-1107-12 |
| Polylactic Acid-Based Blends |
| Administration route | Oral, Other |
| Indication | Encapsulation of pharmaceuticals for controlled drug release, and biodegradable implantable bone plates and fasteners |
| Licence code | LO-1107-11 |
| Synthesis of Novel Functionalised Polyesters by Enzymatic Catalysis |
| Administration route | Undisclosed |
| Indication | Various biomedical applications |
| Licence code | LO-1107-09 |
| Polymeric Electrolytes |
| Administration route | Not applicable |
| Indication | Various biomedical applications |
| Licence code | LO-1107-08 |
| Nasal Triptan |
| Administration route | Nasal |
| Indication | Rapid relief from migraines |
| Licence code | LO-1107-06 |
| Room Temperature Stable Insulin |
| Administration route | Subcutaneous , Nasal , Infusion |
| Indication | Diabetes |
| Licence code | LO-1107-05 |
| Nasal Room Temperature Stable Insulin |
| Administration route | Nasal |
| Indication | Diabetes |
| Licence code | LO-1107-04 |
| Ondansetron Nasal Spray |
| Administration route | Nasal |
| Indication | Nausea and vomiting |
| Licence code | LO-1107-01 |
| Nasal Octreotide |
| Administration route | Nasal |
| Indication | Diarrhoea in cancer |
| Licence code | LO-1107-02 |
| Nasal Calcitonin |
| Administration route | Nasal |
| Indication | Bone pain in opioid-resistant metastatic bone cancer |
| Licence code | LO-1107-03 |
| Once-Daily Oral Histamine for Treatment of Vertigo |
| Administration route | Oral |
| Indication | Vertigo associated with Meničre’s disease |
| Licence code | LO-1007-10 |
| Novel Formulation of Intravenous Anaesthetic |
| Administration route | Injection |
| Indication | Pain |
| Licence code | LO-1007-09 |
| Once-Daily Analgesic for Moderate-to-Severe Pain |
| Administration route | Oral |
| Indication | Moderate-to-severe pain |
| Licence code | LO-1007-08 |
| Bilosomes: Novel Technologies for Vaccine Delivery |
| Administration route | Oral |
| Indication | Vaccine delivery |
| Licence code | LO-0707-03 |
| Transdermal Pain Patch Containing Sufentanil |
| Administration route | Transdermal |
| Indication | Management of moderate-to-severe chronic pain |
| Licence code | LO-0607-10 |
| LabiPatch® |
| Administration route | Transdermal , Topical |
| Indication | Topical treatment for herpes labialis (cold sores ) containing aciclovir |
| Licence code | LO-0607-08 |
| Donepezil Rapidfilm® |
| Administration route | Oral |
| Indication | Treatment of mild-to-moderately severe dementia of the Alzheimer's type |
| Licence code | LO-0607-07 |
| Atopic Dermatitis Patch |
| Administration route | Transdermal , Topical |
| Indication | Atopic dermatitis, common localized eczema, itchy red scaling skin |
| Licence code | LO-0607-09 |
| Quinoline Formulations for Parkinson's Disease |
| Administration route | Oral |
| Indication | Neuroprotection and alleviation of levodopa-induced dyskinesias |
| Licence code | LO-0607-02 |
| Stable (LIQUID) Dispersion of Hydrophilic Molecules/Compounds with Neowater(TM), a Water-Based Nanotechnology from Israel |
| Administration route | Intra-arterial , Subcutaneous , Sublingual , Transdermal , Intravenous , Topical , Intraventricular , Vaginal , Nasal , Inhalation , Ophthalmic , Oral , Injection , Parenteral |
| Indication | Dispersion of hydrophilic drugs and molecules in drug formulations by replacing ordinary water, or using no, or less, organic solvent |
| Licence code | LO-0607-03 |
| Liposomal Technology for Delivery of Active Substances to Cells for Topical or Systemic Applications |
| Administration route | Topical , Injection |
| Indication | Drug delivery in inflammatory and autoimmune diseases, and cancer
|
| Licence code | LO-0507-04 |
| Liposome-Based Depot Formulations for the Systemic Delivery of Therapeutic Proteins and Peptides |
| Administration route | Subcutaneous , Intramuscular, Indication Autoimmune diseases, cancer, endometriosis and precocious puberty |
| Indication | Autoimmune diseases, cancer, endometriosis and precocious puberty |
| Licence code | LO-0507-05 |
| Novel Proprietary NanoEmulsion for Topical, Intra- and Trans-Dermal, and Intransal Drug Delivery |
| Administration route | Transdermal , Topical , Nasal , Other |
| Indication | Systemic delivery of potent peptide, protein and large molecule drugs that are curently only deliverable by injection |
| Licence code | LO-0507-01 |
| Surgical Implant for Treatment and Prevention of Postoperative Infections |
| Administration route | Subcutaneous , Intracerebral , Intralesional , Intramuscular , Parenteral |
| Indication | of surgical site infections and treatment of localised hard and soft tissue infections requiring surgical intervention, such as osteomyelitis |
| Licence code | LO-0407-03 |
| Managing Parkinson's Disease via Continuous Delivery of Apomorphine from a Skin Patch |
| Administration route | Transdermal |
| Indication | Parkinon's disease, restless legs syndrome |
| Licence code | LO-0307-14 |
| Pain Management for Moderate-to-Severe Pain |
| Administration route | Transdermal |
| Indication | Chronic pain (arthritis, lower back pain and cancer); some opportunity for acute pain |
| Licence code | LO-0307-13 |
| LipoBridge®: Facilitating Drug Transport Across Blood-Brain Barrier |
| Administration route | Intra-arterial , Intravenous , Injection , Parenteral |
| Indication | Brain cancer, Alzheimer's and Parkinson's diseases, stroke, trauma and multiple sclerosis |
| Licence code | LO-0307-08 |
| Non-Injectable Product to Provide Basal Insulin via a Skin Patch |
| Administration route | Transdermal |
| Indication | Types 1 and 2 diabetes |
| Licence code | LO-0307-15 |
| Collagen-Based Biodegradable Matrices for Localised Drug Delivery |
| Administration route | Intraperitoneal , Subcutaneous , Intratumoural , Topical , Intralesional , Infusion , Injection |
| Indication | Delivery of anti-infective, analgesic or antineoplastic agents for localised action |
| Licence code | LO-0307-11 |
| Delivery of Targeted Cancer Prodrug |
| Administration route | Intravenous , Topical |
| Indication | Cancer |
| Licence code | LO-0307-09 |
| NanoX®: Lipid-Based Delivery Technology |
| Administration route | Injection |
| Indication | Drug delivery |
| Licence code | LO-0307-01 |
| NanoVNB®: Liposomal Vinorelbine |
| Administration route | Injection |
| Indication | Breast cancer, non-small-cell lung cancer, colon cancer, and head and neck cancer |
| Licence code | LO-0307-02 |
| NanoSphere: Lipid-Based Delivery Technology for Eyes |
| Administration route | Intravenous , Injection |
| Indication | Age-related macular degeneration |
| Licence code | LO-0307-05 |
